Sumitomo Dainippon Pharma to give $3 billion for 10% in RoivantChristian Fernsby ▼ | September 6, 2019
Japan'sSumitomo Dainippon Pharma Co will pay $3 billion for a 10% stake in Swiss drugmaker Roivant Sciences Ltd and interests in five of its biopharmaceutical businesses.
Acquisition Sumitomo Dainippon Pharma
Topics: Sumitomo Dainippon Pharma Roivant
"We look forward to deepening our relationship with Roivant, which has a rich development pipeline, technology platforms, and distinctive talents," Sumitomo Dainippon CEO Hiroshi Nomura said in the statement.
A fifth Roivant business unit will also be transferred before the deal's conclusion, the two companies said. ■